Alkermes plc (NASDAQ:ALKS) Stock Position Decreased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its holdings in shares of Alkermes plc (NASDAQ:ALKS - Free Report) by 3.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,183,100 shares of the company's stock after selling 37,835 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.73% of Alkermes worth $33,115,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of ALKS. V Square Quantitative Management LLC purchased a new position in shares of Alkermes during the 3rd quarter worth $29,000. Signaturefd LLC lifted its holdings in shares of Alkermes by 51.2% during the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company's stock worth $34,000 after acquiring an additional 480 shares during the period. Hexagon Capital Partners LLC raised its stake in Alkermes by 3,841.0% during the second quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company's stock worth $37,000 after purchasing an additional 1,498 shares during the period. GAMMA Investing LLC raised its position in shares of Alkermes by 44.4% in the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company's stock worth $55,000 after buying an additional 703 shares during the period. Finally, Archer Investment Corp boosted its holdings in Alkermes by 28.6% in the third quarter. Archer Investment Corp now owns 4,500 shares of the company's stock valued at $126,000 after acquiring an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 95.21% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ALKS shares. HC Wainwright reiterated a "neutral" rating and set a $37.00 target price on shares of Alkermes in a report on Friday, October 25th. StockNews.com raised shares of Alkermes from a "hold" rating to a "buy" rating in a research note on Sunday, July 28th. Cantor Fitzgerald decreased their price target on shares of Alkermes from $48.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, October 25th. Piper Sandler reissued an "overweight" rating and issued a $37.00 price objective (down from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Finally, Robert W. Baird upped their target price on Alkermes from $37.00 to $38.00 and gave the stock an "outperform" rating in a research report on Thursday, July 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $35.42.

Alkermes Stock Performance

Shares of NASDAQ:ALKS traded up $0.55 during trading on Wednesday, hitting $28.03. 667,002 shares of the company traded hands, compared to its average volume of 1,823,942. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The business's fifty day moving average is $27.81 and its 200-day moving average is $26.30. The stock has a market capitalization of $4.54 billion, a price-to-earnings ratio of 14.09, a PEG ratio of 0.94 and a beta of 0.47. Alkermes plc has a one year low of $22.22 and a one year high of $32.88.

Insiders Place Their Bets

In related news, EVP Craig C. Hopkinson sold 10,471 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total value of $309,208.63. Following the completion of the transaction, the executive vice president now directly owns 99,238 shares of the company's stock, valued at $2,930,498.14. This represents a 9.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.89% of the stock is owned by corporate insiders.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.